

%PDF-1.4 %



## NOTICES

Notice No.	20240805-43	Notice Date	05 Aug 2024
Category	Company related	Segment	Equity
Subject	Listing of Equity Shares of Akums Drugs and Pharmaceuticals Limited		
Attachments	<a href="#">Annexure II.pdf</a> ; <a href="#">Annexure I.pdf</a> ;		
Content			

Trading Members of the Exchange are hereby informed that effective from **Tuesday, August 6, 2024**, the equity shares of **Akums Drugs and Pharmaceuticals Limited** shall be listed and admitted to dealings on the Exchange in the list of 'B' Group of Securities.

<b>Name of the company</b>	Akums Drugs and Pharmaceuticals Limited
<b>Registered Office:</b>	<b>Address:</b> 304, Mohan Place, LSC Saraswati Vihar, Delhi-110034, India. <b>Tel:</b> + 91 11 6904 1000 <b>Email:</b> <a href="mailto:cs@akums.net">cs@akums.net</a> <b>Website:</b> <a href="http://www.akums.in">www.akums.in</a>
<b>No. of Securities</b>	157393988 Equity Shares of Rs.2/- each fully paid up
<b>Distinctive Number range</b>	1 To 157393988
<b>Scrip ID on BOLT System</b>	AKUMS
<b>Abbreviated Name on BOLT System</b>	AKUMS
<b>Scrip Code</b>	544222
<b>ISIN No.</b>	INE09XN01023
<b>Market Lot</b>	1
<b>Issue Price for the current Public issue</b>	Rs. 679/- per share (Face Value of Rs. 2/- and premium of Rs. 677/-)
<b>Date of Allotment in the public issue:</b>	August 2, 2024
<b>Pari Pasu</b>	Yes
<b>Financial Year</b>	Mar-31
<b>Lock in detail</b>	<b>As per Annexure I</b>
<b>Shareholding Pattern</b>	<b>As per Annexure II</b>

a) Trading Members may note that as per the guidelines issued by SEBI dated 16th February 2000, securities of the company will only be traded in Dematerialised form.

b) Further the trading members may please note that the above mentioned scrip will be a part of **Special Pre-open Session (SPOS) on Tuesday, August 6, 2024**. For further information on SPOS, the trading members are requested to refer to the Exchanges notice no. 20120216-29 dated February 16, 2012 on Enabling Special Pre-open Session for IPOs & Relisted Scrips.

c) The company has informed the Exchange that in respect of shares in demat form, necessary corporate action has been executed to have the lock-in period marked in the depository records.

d) The Registrar to the issue as mentioned in the prospectus is given below

<b>Link Intime India Private Limited</b>
<b>Registered Office:</b> C-101, 1 st Floor 247 Park Lal Bahadur Shastri Marg Vikhroli (West) Mumbai 400 083 Maharashtra, India
<b>Telephone:</b> +91 8108114949
<b>Email Id:</b> <a href="mailto:akumsdrugs.ip@linkintime.co.in">akumsdrugs.ip@linkintime.co.in</a>
<b>Website:</b> <a href="http://www.linkintime.com">www.linkintime.com</a>

**Investor Grievance Id:** [akumsdrugs.ipo@linkintime.co.in](mailto:akumsdrugs.ipo@linkintime.co.in)

**Contact Person:** Shanti Gopalkrishnan

**SEBI Registration No:** INR000004058

e) In case members require any clarifications on the subject matter of this notice, they may please contact any of the following:

<b>a) At the company:</b>  Dharamvir Malik Company Secretary and Compliance Officer	<b>Address:</b> 304, Mohan Place, LSC Saraswati Vihar, Delhi-110034, India. <b>Tel:</b> + 91 11 6904 1000 <b>Email:</b> <a href="mailto:cs@akums.net">cs@akums.net</a> <b>Website:</b> <a href="http://www.akums.in">www.akums.in</a>
<b>b) At the Exchange:</b>  Mr. Prasad Bhide Senior Manager	Tel.: (91) 022 2272 8388

**Hardik Bhuta**

**Assistant General Manager**

**Monday, August 05, 2024**